{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:49:00Z","timestamp":1791676140488,"version":"4.3.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07278-5","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:45:46Z","timestamp":1789501546000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early deep response to cilta-cel as 2nd CAR T-Cell therapy after CELMoD-based bridging for advanced multiple myeloma"],"prefix":"10.1007","volume":"105","author":[{"given":"Henrik","family":"Niklas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"V\u00f6lkl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marietta","family":"Truger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut","family":"Wendelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Strifler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"G\u00e4rtner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Knop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"7278_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5001\/omj.2013.02","volume":"28","author":"K Al-Farsi","year":"2013","unstructured":"Al-Farsi K (2013) Multiple Myeloma: An Update. Oman Med J 28:3\u201311. https:\/\/doi.org\/10.5001\/omj.2013.02","journal-title":"Oman Med J"},{"key":"7278_CR2","doi-asserted-by":"publisher","first-page":"108","DOI":"10.5603\/njo.108723","volume":"76","author":"G Charli\u0144ski","year":"2026","unstructured":"Charli\u0144ski G, Vesole DH, Jurczyszyn A (2026) Multiple myeloma in 2026 \u2014 current guidelines and new therapies. Nowotw J Oncol 76:108\u2013127. https:\/\/doi.org\/10.5603\/njo.108723","journal-title":"Nowotw J Oncol"},{"key":"7278_CR3","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1200\/JCO-24-01893","volume":"43","author":"H Avet-Loiseau","year":"2025","unstructured":"Avet-Loiseau H, Davies FE, Samur MK, Corre J, D\u2019Agostino M, Kaiser MF (2025) u. a. International Myeloma Society\/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma. J Clin Oncol 43:2739\u20132751. https:\/\/doi.org\/10.1200\/JCO-24-01893","journal-title":"J Clin Oncol"},{"key":"7278_CR4","doi-asserted-by":"publisher","first-page":"e260001","DOI":"10.6004\/jnccn.2026.0001","volume":"24","author":"SK Kumar","year":"2026","unstructured":"Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Baz R (2026) u. a. Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw 24:e260001. https:\/\/doi.org\/10.6004\/jnccn.2026.0001","journal-title":"J Natl Compr Canc Netw"},{"key":"7278_CR5","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","volume":"366","author":"PL McCarthy","year":"2012","unstructured":"McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG (2012) u. a. Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma. N Engl J Med 366:1770\u20131781. https:\/\/doi.org\/10.1056\/NEJMoa1114083","journal-title":"N Engl J Med"},{"key":"7278_CR6","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD (2021) u. a. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398:314\u2013324. https:\/\/doi.org\/10.1016\/S0140-6736(21)00933-8","journal-title":"Lancet"},{"key":"7278_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.70134","author":"ME Alvaro","year":"2026","unstructured":"Alvaro ME, Martino EA, Caserta S, Skafi M, Bruzzese A, Amodio N (2026) u. a. Targeting Ikaros and Aiolos: Next-Generation Cereblon E3 Ligase Modulators in MM. Eur J Haematol. https:\/\/doi.org\/10.1111\/ejh.70134. ejh.70134","journal-title":"Eur J Haematol"},{"key":"7278_CR8","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","volume":"34","author":"CC Bjorklund","year":"2020","unstructured":"Bjorklund CC, Kang J, Amatangelo M, Polonskaia A, Katz M, Chiu H (2020) u. a. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. Leukemia 34:1197\u20131201. https:\/\/doi.org\/10.1038\/s41375-019-0620-8","journal-title":"Leukemia"},{"key":"7278_CR9","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/17474086.2024.2382897","volume":"17","author":"Y Liu","year":"2024","unstructured":"Liu Y, Mo CC, Hartley-Brown MA, Sperling AS, Midha S, Yee AJ (2024) u. a. Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide. Expert Rev Hematol 17:445\u2013465. https:\/\/doi.org\/10.1080\/17474086.2024.2382897","journal-title":"Expert Rev Hematol"},{"key":"7278_CR10","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1182\/blood.2024027616","volume":"147","author":"L Rieger","year":"2026","unstructured":"Rieger L, Irlinger K, F\u00fcchsl F, Tietje M, Purcarea A, Barbian N (2026) u. a. Boosting CAR T-cell efficacy by blocking proteasomal degradation of membrane antigens. Blood 147:534\u2013546. https:\/\/doi.org\/10.1182\/blood.2024027616","journal-title":"Blood"},{"key":"7278_CR11","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1182\/bloodadvances.2023012066","volume":"8","author":"KR Reyes","year":"2024","unstructured":"Reyes KR, Liu Y-C, Huang C-Y, Banerjee R, Martin T, Wong SW (2024) u. a. Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma. Blood Adv 8:2207\u20132216. https:\/\/doi.org\/10.1182\/bloodadvances.2023012066","journal-title":"Blood Adv"},{"key":"7278_CR12","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1182\/bloodadvances.2023012416","volume":"8","author":"G Ledergor","year":"2024","unstructured":"Ledergor G, Fan Z, Wu K, McCarthy E, Hyrenius-Wittsten A, Starzinski A (2024) u. a. CD4\u2009+\u2009CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy. Blood Adv 8:3562\u20133575. https:\/\/doi.org\/10.1182\/bloodadvances.2023012416","journal-title":"Blood Adv"},{"key":"7278_CR13","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1007\/s00277-025-06340-y","volume":"104","author":"P Mobascher","year":"2025","unstructured":"Mobascher P, Engelhardt M, W\u00e4sch R (2025) Successful sequential application of CAR T-cell-therapies in relapsed refractory multiple myeloma. Ann Hematol 104:2055\u20132058. https:\/\/doi.org\/10.1007\/s00277-025-06340-y","journal-title":"Ann Hematol"},{"key":"7278_CR14","doi-asserted-by":"publisher","first-page":"4624","DOI":"10.1182\/bloodadvances.2025016712","volume":"9","author":"T Richardson","year":"2025","unstructured":"Richardson T, Holtick U, Frenking J-H, Tharmaseelan H, Balke-Want H, Fl\u00fcmann (2025) R, u. a. Sequential BCMA CAR T-cell therapy in refractory multiple myeloma. Blood Adv 9:4624\u20134630. https:\/\/doi.org\/10.1182\/bloodadvances.2025016712","journal-title":"Blood Adv"},{"key":"7278_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41408-026-01474-2","volume":"16","author":"MS Rana","year":"2026","unstructured":"Rana MS, Fernandez-Pol S, Jensen A, Hovanky V, Velayati A, Oak JS (2026) u. a. Dynamics of BCMA expression in patients with relapsed\/refractory multiple myeloma receiving BCMA-directed CAR-T therapy. Blood Cancer J 16:79. https:\/\/doi.org\/10.1038\/s41408-026-01474-2","journal-title":"Blood Cancer J"},{"key":"7278_CR16","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1182\/blood-2018-99-115200","volume":"132","author":"EJ Dettman","year":"2018","unstructured":"Dettman EJ, Rigat F, Albert J, Barnard R, Birchler M, Deghenhardt Y (2018) u. a. Expression of Myeloma Cell and Soluble B-Cell Maturation Antigen (BCMA) in Relapsed and Refractory Multiple Myeloma Patients Treated with GSK2857916 in BMA117159. Blood 132:1977\u20131977. https:\/\/doi.org\/10.1182\/blood-2018-99-115200","journal-title":"Blood"},{"key":"7278_CR17","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee H, Ahn S, Maity R, Leblay N, Ziccheddu B, Truger M (2023) u. a. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med 29:2295\u20132306. https:\/\/doi.org\/10.1038\/s41591-023-02491-5","journal-title":"Nat Med"},{"key":"7278_CR18","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.3324\/haematol.2022.282510","volume":"108","author":"N Gagelmann","year":"2023","unstructured":"Gagelmann N, Ayuk FA, Klyuchnikov E, Wolschke C, Berger SC, Kr\u00f6ger N (2023) Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: a meta-analysis of 723 patients. Haematologica 108:2799\u20132802. https:\/\/doi.org\/10.3324\/haematol.2022.282510","journal-title":"Haematologica"},{"key":"7278_CR19","doi-asserted-by":"publisher","first-page":"5764","DOI":"10.1182\/blood-2025-5764","volume":"146","author":"N Attar","year":"2025","unstructured":"Attar N, Shome R, Samur M, Gustine J, Graham C, Gallagher KM (2025) u. a. The efficacy of cilta-cel after a prior BCMA-directed CAR T-cell therapy in relapsed\/refractory multiple myeloma. Blood 146:5764\u20135764. https:\/\/doi.org\/10.1182\/blood-2025-5764","journal-title":"Blood"},{"key":"7278_CR20","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","volume":"18","author":"DL Wagner","year":"2021","unstructured":"Wagner DL, Fritsche E, Pulsipher MA, Ahmed N, Hamieh M, Hegde M (2021) u. a. Immunogenicity of CAR T cells in cancer therapy. Nat Rev Clin Oncol 18:379\u2013393. https:\/\/doi.org\/10.1038\/s41571-021-00476-2","journal-title":"Nat Rev Clin Oncol"},{"key":"7278_CR21","doi-asserted-by":"publisher","first-page":"6154","DOI":"10.1038\/s41467-025-60980-2","volume":"16","author":"D Atanackovic","year":"2025","unstructured":"Atanackovic D, Luetkens T, Schneider D, Hu P, Wang X, Shetty AC (2025) u. a. Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma. Nat Commun 16:6154. https:\/\/doi.org\/10.1038\/s41467-025-60980-2","journal-title":"Nat Commun"},{"key":"7278_CR22","doi-asserted-by":"publisher","first-page":"101158","DOI":"10.1016\/j.xcrm.2023.101158","volume":"4","author":"P Strati","year":"2023","unstructured":"Strati P, Li X, Deng Q, Marques-Piubelli ML, Henderson J, Watson G (2023) u. a. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFN\u03b3-expressing CD8 T cells. Cell Rep Med 4:101158. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101158","journal-title":"Cell Rep Med"},{"key":"7278_CR23","doi-asserted-by":"publisher","unstructured":"Dahunsi D, Eleanya C, Akintunde A, Oluwole O Prolonged Cytopenia with CAR-T Cell Therapy and Management Recommendations. Clin Hematol Int [Internet]. 2025 [zitiert 6. M\u00e4rz 2026];7. https:\/\/doi.org\/10.46989\/001c.126463","DOI":"10.46989\/001c.126463"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07278-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07278-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07278-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:05:53Z","timestamp":1791673553000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07278-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":23,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["7278"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07278-5","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"24 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent was obtained from the patient for publication.","order":1,"name":"Ethics","label":"Patient consent and Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"421"}}